Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Fierce Pharma
Novo's longtime CEO Lars Fruergaard Jørgensen to step down
It’s the end of an era at Novo as longtime CEO Lars Fruergaard Jørgensen—who shepherded the company through its GLP-1 growth boom—heads for the exit.
Fraiser Kansteiner
May 16, 2025 9:41am
Novo inks $2.2B deal for Septerna's preclinical obesity programs
May 14, 2025 7:00am
FDA lifts hold on Amgen's phase 1 obesity study
May 2, 2025 10:10am
Ascletis sees no benefit to high, fast oral GLP-1 dose titration
Apr 23, 2025 7:25am
Pfizer axes oral GLP-1 asset, blowing hole in obesity plan
Apr 14, 2025 7:34am
Novo inks $1B deal for Lexicon’s preclinical obesity prospect
Mar 28, 2025 7:30am
